Impact Factor
4.85
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
31.84
40,764 total citations
h5-index
276
h5 depth signal
Cited share
79.3%
1,071 of 1,350
Total citations
40,764
Citation footprint
Metric signal
34.47
External metric anchor
Self-citation
0.9%
350 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,990
United Kingdom
1,033
Germany
570
Canada
468
China
431
Citing Fields of Research
Immunology
805
Oncology
506
Virology
445
Genetics & Genomics
421
Medical Ethics
371
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
16,514
Articles tracked across the journal lifetime
Indexed publication set
1,350
1,071 cited publications
Last 12 months
749
62.4 publications/month
Open access share
42.7%
320 OA publications in the last year
Leading citing country
United States
2,990 citing publications
Leading citing field
Immunology
805 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Jan. 1995-
v1n1,Jan. 1995-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Immunology
Genetics & Genomics
Diabetes
Lung Cancer
Oncology
Cardiology
Broad Categories
Medicine
Molecular Biology
Immunology
Genetics & Genomics
Medical Ethics
Neurodegenerative Disorders
Virology
Lung Cancer
Diabetes
MeSH Descriptors
Medicine
Molecular Biology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1038/s41591-026-04701-2
Open DOI
Waiting to get sick enough
02
DOI 10.1038/s41591-026-04692-0
Open DOI
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy
03
DOI 10.1038/d41591-026-00052-0
Open DOI
A reality check for autoimmune CAR T cells
04
DOI 10.1038/s41591-026-04719-6
Open DOI
Conversational brain AI for adaptive epilepsy care
05
DOI 10.1038/s41591-026-04687-x
Open DOI
Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight reduction and cardiometabolic benefit in randomized trials; however, prospective implementation evidence from digital care models and female sex co...
06
DOI 10.1038/s41591-026-04715-w
Open DOI
EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial
D2C7-ATC is a recombinant antibody-toxin conjugate (ATC) targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII). We conducted a single-arm, single-site, open-label phase 1 trial evaluating a si...
07
DOI 10.1038/s41591-026-04699-7
Open DOI
Only time will tell
08
DOI 10.1038/d41591-026-00051-1
Open DOI
Optogenetic therapy shows early promise for treating retinitis pigmentosa
09
DOI 10.1038/d41591-026-00050-2
Open DOI
Hidden race disparities in cancer treatment toxicity
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.